Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Inclusion Criteria:

- 18 to 80 years of age inclusive

- Historical diagnosis of type 2 diabetes mellitus (T2DM) (at least 3 months),
experiencing inadequate glycemic control on current regimen of diet and exercise or on
a stable maximal tolerated dose of metformin, maintained for approximately 8 weeks
prior to screening.

- HbA1c >=7.0 percent (%) and <=10%.

- Hemoglobin >=11 grams per deciliter (g/dL) (>=110 grams per liter [g/L]) for males and
>=10 g/dL (>=100 g/L) for females.

- Body mass index <=40 kilograms per squared meter (kg/m^2)

- Male or female

- Able and willing to provide informed consent.

Exclusion Criteria:

- Type 1 diabetes mellitus

- History of cancer that has not been in full remission for at least 3 years before
screening. (A history of squamous cell or basal cell carcinoma of the skin or treated
cervical intra-epithelial neoplasia I or II is allowed).

- Personal or family history of medullary thyroid carcinoma or multiple endocrine
neoplasia type 2.

- History of acute or chronic pancreatitis.

- History of thyroid dysfunction or an abnormal (i.e., outside the normal reference
range) thyroid function test assessed by thyroid stimulating hormone at screening.

- Severe gastroparesis, i.e., requiring regular therapy within 6 months before
screening.

- History of significant gastrointestinal (GI) surgery that in the opinion of the
investigator is likely to significantly affect upper GI or pancreatic function

- History of severe hypoglycemia unawareness

- Diabetic complications or any other clinically significant abnormality .

- Clinically significant Cardiovascular (CV) and/or cerebrovascular disease within 3
months before screening

- QT interval corrected for heart rate according to Fridericia's formula (QTcF) > 470
milliseconds (msec).

- ALT >2.5x upper limit of the normal range (ULN) or bilirubin >1.5xULN (isolated
bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin
<35%).

- Current active liver or biliary disease (with the exception of Gilbert's syndrome or
asymptomatic gallstones or otherwise stable chronic liver disease per investigator
assessment).

- Estimated glomerular filtration rate (eGFR) <=30 milliliter (mL)/minute (min)/1.73
squared meter (m^2) (calculated using the Modification of Diet in Renal Disease [MDRD]
formula) at screening.

- Fasting triglyceride level >750 milligrams per deciliter (mg/dL) at screening.

- Hemoglobinopathy that may affect proper interpretation of HbA1c.

- Medical or psychiatric disorders that would preclude effective participation in study.

- Use of oral or systemically injected glucocorticoids within the 3 months before
randomization or high likelihood of a requirement for prolonged treatment (>1 week) in
the 6 months following randomization.

- Use of dipeptidyl peptidase-IV inhibitors within the 3 months before randomization.

- History of alcohol or substance abuse within one year before screening.

- Known allergy to albiglutide or any product components (including yeast and human
albumin), any other glucagon-like peptide-1 (GLP-1) analogue, or other study
medication's excipients OR other contraindications (per the prescribing information)
for the use of potential study medications.

- A positive pre-study drug/alcohol screen.

- A positive test for human immunodeficiency virus (HIV) antibody.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).